Hepatotoxicity in the treatment of tuberculosis using moxifl oxacincontaining regimens

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 9, 2011, Pages 1275-1276

  Roberts, Catherine H ^a   Smith, Colette ^b   Breen, Ronan ^c   Gadhok, Radha ^a   Murphy, Michael ^a   Aryee, Anna ^a   Cropley, Ian ^a   Bhagani, Sanjay ^a   Hopkins, Susan ^a   Lipman, Marc ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

CLINICAL ASSESSMENT; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG WITHDRAWAL; HEPATITIS; HUMAN; LETTER; LIVER CIRRHOSIS; LIVER TOXICITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TUBERCULOSIS; VIRUS HEPATITIS;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; COHORT STUDIES; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; QUINOLINES; RETROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 80051689829     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0352     Document Type: Letter

References (5)

1. Iannini P B. The safety profi le of moxifl oxacin and other fl uoroquinolones in special patient populations. Curr Med Res Opin 2007; 23: 1403-1413. (Pubitemid 46998448)
2. Drug safety update. MHRA. August 2008; 2(1): 8.
3. Dorman S E, Johnson J L. Substitution of moxifl oxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
4. Burman W J, Goldberg S, Johnson J L. Moxifl oxacin versus ethambutol in the fi rst 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338. (Pubitemid 44156613)
5. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS table for grading the severity of adult adverse events. Bethesda, MD: US Department of Health and Human Services, 1992.